Literature DB >> 31647686

Pediatric Ocular Acne Rosacea: Clinical Features and Long Term Follow-Up of Sixteen Cases.

Oya Donmez1, Yonca Aydın Akova1.   

Abstract

Purpose: To report the clinical characteristics, treatment modalities and long term follow-up of 16 pediatric ocular acne rosacea patients.
Methods: The medical records of pediatric ocular acne rosacea patients were reviewed.
Results: There were 16 patients with a mean age of 7.7 ± 5 (1-16) years. The mean follow-up period was 52.8 ± 52 (3-150) months. Eight patients had skin involvement. The mean duration of delay for diagnosis was 16.2 ± 5.1 (4-48) months. Nine patients had a delayed diagnosis. Meibomitis, blepharitis, lid telangiectasia, and conjunctival hyperemia were present in all cases. Systemic antibiotics were prescribed in 12 patients. The mean delay in diagnosis was longer in patients with conjunctival/corneal involvement (p = .001) and these patients required longer systemic treatment (p = .001). Complete remission was achieved in 87.5% of cases.
Conclusion: Children presenting with a long history of ocular irritation, meibomian gland disease, recurrent chalazia and peripheral corneal infiltrates should alert ophthalmologists to consider the diagnosis of ocular acne rosacea even in the absence of skin changes.

Entities:  

Keywords:  Acne rosacea; blepharitis; chalazia; childhood; meibography

Year:  2019        PMID: 31647686     DOI: 10.1080/09273948.2019.1668951

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  2 in total

1.  Retrospective investigation of peripheric blood sampling in pediatric chalazion patients.

Authors:  Cagri Ilhan
Journal:  Int Ophthalmol       Date:  2021-01-02       Impact factor: 2.031

2.  Multivariate analysis of the effect of Chalazia on astigmatism in children.

Authors:  Lijuan Ouyang; Xinke Chen; Lianhong Pi; Ning Ke
Journal:  BMC Ophthalmol       Date:  2022-07-17       Impact factor: 2.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.